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A randomized trial of a pharmacist-delivered intervention (PI) versus usual care (UC) was conducted; 689 subjects with known
coronary heart disease were recruited from cardiac catheterization laboratories. Participants in the PI condition received 5
pharmacist-delivered telephone counseling calls post-hospital discharge. At one year, 65% in the PI condition and 60% in the
UC condition achieved an LDL-C level < 100mg/dL (P = .29); mean statin adherence was 0.88 in the PI, and 0.90 in the UC
(P = .51). The highest percentage of those who reached the LDL-C goal were participants who used statins as opposed to those
who did not use statins (67% versus 58%, P = .05). However, only 53% and 56% of the patients in the UC and PI conditions,
respectively, were using statins. We conclude that a pharmacist-delivered intervention aimed only at improving patient adherence
is unlikely to positively aﬀect outcomes. Eﬀorts must be oriented towards inﬂuencing physicians to increase statin prescription
rates.
1.Introduction
Cardiovascular disease (CVD) is a leading cause of mortality
worldwide.Anestimated79millionAmericanshaveCVD,of
whom almost 16 million (20%) have coronary heart disease
(CHD) [1]. Secondary prevention eﬀorts aimed at treating
risk factors such as dyslipidemia have reduced the morbidity
and mortality related to CVD [2]. Numerous studies have
demonstrated a reduction in mortality with the use of 3-
hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
(statin) therapy [3–7]. The serum low-density lipoprotein
c h o l e s t e r o l( L D L - C )g o a l ,a sr e ﬂ e c t e di nt h et r e a t m e n t
guidelines of the Adult Treatment Panel of the National
Cholesterol Education Program (NCEP ATP-III) [8], is
<100mg/dL. An update of the guidelines in 2004 supports
a nL D L - Cg o a lo f7 0m g / d lf o rs e c o n d a r yp r e v e n t i o n[ 4].
Critical to the success of any medication is adherence to
the prescribed dosage regimen. However, long-term adher-
ence for many medications is poor. Prior studies of preven-
tive interventions have documented inadequate adherence
in approximately 50 percent of patients [9–11]. Signiﬁcant
numbers of patients either never ﬁll or do not take their
medications as prescribed. Among those who do initially
take the prescribed medications, many patients discontinue
medications over time. Observed discontinuation rates are
directly proportional to length of time on the medication,
and range from 15% to 74% [12–16]. None of these studies
include patients who are of status post a coronary event or
procedure.
While statin medication use has increased in the last
decade, use and adherence to statins remains suboptimal
[12, 17, 18]. Using the National Health and Nutrition2 Cholesterol
Examination Survey (NHANES) 2003-2004, Mann and
colleagues reported statin use by only 19.6% of US adults
with high LDL-C levels in 1999-2000, 27.3% in 2001-2002,
and 35.9% in 2003-2004, suggesting increasing but still
suboptimal use (P-value for trend <.001) [17]. In a study
of New Jersey Medicaid data, only 9.2% of patients ﬁlled a
statin prescription within 90 days of hospital discharge for
acute MI in 1995 as compared to 43.1% of patients in 2003
(P-value for trend <.001), however, only 25% of those who
ﬁlled an initial prescription continue to take statins 5 years
after initiation of therapy [12]. In a more recent analysis
from Canada, 2-year adherence rates ranged from 48% for
ﬂuvastatin to 63% for atorvastatin [18].
Pharmacist-delivered interventions may improve adher-
ence to prescribed lipid-lowering medications. The Phar-
macist Assisted Compliance Trial (PACT, ClinicalTrials.gov
Identiﬁer: NCT00848224) was a randomized controlled trial
testing a pharmacist-delivered program to improve adher-
ence to lipid-lowering pharmacologic therapy in patients
with known CHD [19] .T h eo b j e c t i v eo ft h i ss t u d yw a st o
compare intervention and usual care conditions for LDL-C
goal attainment and proportion of prescribed lipid-lowering
medication taken by subjects over a one-year period.
2.MaterialsandMethods
2.1. Study Design and Population. The overall goal of
this study was to implement and evaluate the eﬀects
of a pharmacist-delivered intervention (PI) designed to
improve LDL-C goal attainment according to the NCEP
ATP-III Guidelines and prescribed lipid-lowering medi-
cation adherence in patients with known CHD. In this
two-condition randomized clinical trial, the intervention
condition included: (1) a computer-based tracking system
designed to facilitate follow-up of patients who were initially
seen for a CHD clinical event at UMass Memorial Medical
Center (UMMMC); (2) an initial inpatient contact and a
series of coordinated patient-centered pharmacist-delivered
telephone counseling contacts to improve adherence to
prescribed medications. The tracking system was developed
based on a communication system using Lotus Notes from
IBM (Lotus Notes R5.0.11). Eligibility data, demographic
information, and contact and proxy contact information
were entered into the system. The system was shared by
the study team. We used it to track eligible and ineligible
patients, and facilitate timely scheduling of assessments and
intervention sessions. Multiple levels of password protection
were utilized to ensure data security. The pharmacists also
provided feedback and recommendations to the patients’
physicians and nurse practitioners. The pharmacist had
access to the lipid values during the study.
The study population consisted of 689 patients recruited
from the cardiac catheterization laboratories of UMMMC, a
tertiary care hospital in central Massachusetts. A patient was
eligible for the study if he/she was between the ages of 30 and
85 years and had CHD deﬁned as the presence of at least one
coronary lesion ≥50% at the time of coronary angiography.
Patients could have a history of prior CHD, or this could
have been their ﬁrst such diagnosis. Patients were excluded
if they were unable or unwilling to give informed consent in
English, had a history of intolerance to two or more statin
drugs, planned to move out of the area within one year of
recruitment, had a poor prognosis such that life expectancy
was estimated to be <5 years, had a major psychiatric illness,
or had no telephone.
Patients were randomly assigned to the UC condition or
to the PI condition. The UC condition consisted of normal
clinical care as determined by the patient’s provider. Patients
inthePIconditionwereseenbyoneofthestudypharmacists
prior to discharge. This allowed the pharmacist to establish
a relationship with the patient, explain the pharmacist’s
role in the study, provide education about all discharge
medications including a medication card which listed all
medications and their manner of use, and set the framework
for the follow-up telephone calls. The pharmacist-delivered
telephone counseling calls took place at two weeks, and at 1,
3, 6, and 9 months following discharge. The goal was to assist
patients to remain adherent to prescribed statins and other
medications, and also promote adherence to AHA guidelines
forLDL-C.Duringthesecalls,pharmacistsutilizedapatient-
centeredcounselingalgorithm(addressgeneralissues,assess,
advise, assist, arrange follow-up; see the appendices for
details) to help patients develop a medication adherence
plan. In addition, the pharmacist facilitated scheduling of
repeat blood draws for lipid measurement and provided
information, guidelines; and prompts to the patient and to
the patient’s physician or nurse practitioner with regard to
LDL-C management. Speciﬁcally, the provider received an
emailed summary of the discussion after each pharmacist
contact with the patient. The email included three categories
(i.e., adherence, CAD, and hyperlipidemia) along with
recommendationsforeach.Atthein-patientvisit,patientsin
the PI condition were also provided an educational packet,
a dietary goal booklet, and a pillbox. Participants in the PI
condition also were mailed updated medication cards if their
medication regime had changed.
The study pharmacists were trained in the delivery of
patient-centered counseling [20, 21] and followed patient-
centered protocols for the in-patient and telephone contacts.
This training included a 4-hour meeting that presented
pharmacists with an orientation to the study (i.e., back-
ground, design, and timeline), the theoretical framework
for the intervention, patient-centered counseling protocols
and opportunities for role-playing the protocols among
themselves. An additional one-hour role-playing session was
completed within 2 weeks of the ﬁrst training session, and
provided further opportunities for role-playing potential
patient scenarios. During the individual session the phar-
macists were provided with immediate feedback regarding
their counseling skills, and had an opportunity to correct
problems. For quality control, one of the investigators (Dr.
Milagros C. Rosal) listened to telephone call recordings
monthly for the ﬁrst 2 months and then bimonthly through
year 2. Two booster sessions were conducted within the
2 years of the study intervention, providing the pharma-
cists with feedback on their counseling skills and eliciting
discussion of challenges encountered with patients. The
pharmacist was told of the quality control procedures andCholesterol 3
verbalinformedconsentwasobtainedfromthepatientwhen
a call was recorded.
The patient was the unit of randomization and analysis.
Randomization was conducted by a statistician who was not
involved with the intervention. The study was conducted
between September 2000 and August 2005. The Institutional
Review Boards of the University of Massachusetts Medical
School approved all subject recruitment, intervention, and
data collection procedures.
2.2. Data Collected. Data collected included a serum LDL-
C level at 12 months and pharmacy reﬁll information
between the baseline and one-year study participation dates.
Pharmacy reﬁll records were obtained from all pharmacies
where each patient obtained their medications. They were
our primary measure for ascertaining patient adherence to
statin, angiotensin-converting enzyme (ACE) inhibitor, and
beta-blocker medications. The number of diseased vessels
as measured by coronary angiography was obtained from
each patient’s catheterization report. Patient demographic
characteristics were measured at baseline. Data measured
at one year included a blood lipid proﬁle, a 24-hour diet
and physical activity recall, smoking status, and measures of
height, weight, and waist circumference.
2.3. Outcomes. The primary outcome evaluated at one year
included percentage of patients with a serum low-density
lipoprotein cholesterol (LDL-C) level <100mg/dl; the sec-
ondary outcome included the proportion of prescribed statin
medication taken by patients as measured by a continuous
multiple-interval (CMA) based on pharmacy records. The
CMA is the ratio of days supply obtained to total days
between reﬁll records [22]. Other secondary outcomes
evaluated at one year included the proportion of patients
prescribed ACE inhibitor and beta-blocker medication.
Adherence to these medications was also measured by CMA.
2.4. Sample Size. The sample size chosen was a balance
between cost/resources, study complexity, and statistical
testingpower.With345patientsineachcondition,thisstudy
hadsuﬃcientpower(90%orgreater)todetectachangeof10
percentage points in the rate of subjects achieving the LDL-C
goal of <100mg/dl between two conditions even under the
most conservative conditions. This sample size also allowed
suﬃcient power to detect a change in mean CMA of 0.12
even in a conservative scenario of 40% on therapy in each
condition.
2.5. Statistical Analysis. The dichotomous value of achieving
the goal LDL-C was compared between the two randomized
conditions using a Fisher’s exact test with an alpha level of
0.05 used for statistical signiﬁcance. Since the distribution
of CMA values was approximately normal, it was compared
using a t-test between two conditions. Logistic regression
analysis was conducted for predicting LDL-C goal by inter-
vention group adjusted for covariates such as age, gender,
and statin medication adherence.
3. Results
Of 689 patients recruited, 338 were randomized to the
control condition and 351 to the intervention condition.
A total of 559 (81%) had complete pharmacy records
and were included in the ﬁnal analysis. There was no
statistically signiﬁcant diﬀerence between intervention and
control subjects in the percentage of subjects with complete
pharmacy records (80% versus 82%, P = .50). Of the
total patient population, 554/689 or 80.4% had a one-
year LDL-C value available; 83.5% in intervention versus
77.2% in the control condition. This diﬀerence was due
to a greater number of subjects in the control condition
having triglycerides ≥400mg/dl, precluding the calculation
of LDL-C. In total, 65.5% of the participants had both
pharmacy and LDL-C measures, with no signiﬁcant diﬀer-
ence between the conditions (66.4% versus 64.5% for inter-
vention versus control, resp.). Figure 1 is a ﬂowchart that
outlines the recruitment, follow-up, and sample used for the
analysis.
The mean age of participants was 60 years, with an
average body mass index (BMI) of 30kg/m2.S i x t yp e r c e n t
were male, 68% were married or lived with partner, and
90% were white. Forty-ﬁve percent had a high school or
less education (Table 1). Participants in the UC condition
were more likely to be smokers, but were not statistically
diﬀerent from the PI participants in any other characteristic,
including demographics, BMI, and catheterization-assessed
severity index [23, 24].
Table 2 presents the results of lipid measures. At 12
months, 65% achieved the goal LDL-C level of <100mg/dl
in the PI condition, and 60% achieved this in the UC
condition (P = .29). Averagelevelsoftotalcholesterol,HDL-
C, LDL-C, and triglycerides also were similar between the
two conditions.
Three hundred and thirty-two subjects (48%) used statin
therapy during the study. Of these 85% used atorvastatin,
13% simvastatin, 5% pravastatin, 2% ﬂuvastatin, and 1%
lovastatin. Seventy-four percent of statin reﬁlls were written
for a 30-day supply. At one-year, only 53% and 56% of
the participants in the UC and PI conditions, respectively,
wereusingstatinmedication.Useofnonstatinlipid-lowering
medication was infrequent, and these medications included
fenoﬁbrate (9 patients), gemﬁbrozil (7 patients), slow-
release niacin (6 patients), colesevelam (4 patients), and
cholestyramine (1 patient).
Table 3 presents adherence with statin medications. The
CMA for statin medication use was 0.88 (standard deviation
(SD) = 0.3) in the PI condition (referring to the patient
being 88% adherent to their statins medication), and 0.90
(SD = 0.3) in the UC condition (P = .51). The number of
statin reﬁlls and total days on statins were similar in the two
conditions.
Adherence to beta-blockers and ACE inhibitors is also
noted in Table 3, showing no statistical diﬀerences in the use
of these medications in the two conditions. The number of
beta- blocker and ACE inhibitor reﬁlls was also similar in the
two conditions, and, as was the case with statin therapy, very
high (>90%) in all conditions.4 Cholesterol
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Figure 1: Study recruitment, follow-up, and sample used for the PACT analysis.
Multivariate logistic regression model results predicting
LDL-C <100mg/dl included variables of study condition,
gender, age, and CMA. Results indicated that females were
less likely to reach the LDL-C goal (odd ratio = 0.62, 95%
conﬁdence interval: 0.39–0.97, P = .04); and patients aged
61–70 were more likely to reach goal (odd ratio = 2.27, 95%
conﬁdence interval: 1.18–4.34, P = .01, referent group: age
< 51). Patients with greater statin CMA levels also had a
higher likelihood of attaining the LDL-C goal (odd ratio
for CMA > 1 = 2.23, 95% conﬁdence interval: 1.17–4.24,
P = .01, referent group: CMA = 0). Study condition was
not signiﬁcantly associated with LDL-C goal attainment.
We considered several other variables such as depression,
however, they were not signiﬁcantly predicting LDL goal,
thus were not included in the ﬁnal model.
Since a smaller proportion of females reached LDL goals,
we examine diﬀerences in the measurements by gender.
Compared to men, women were on average older, had
higher BMI, had lower education level, were less likely to be
married/livewithapartner,andhadalowercoronarydisease
severity score. Women were more likely to use a pillbox, took
medication more often, and were more likely to believe that
spirituality inﬂuences health.
WeexaminedstatinmedicationuseandLDL-Coutcome.
The highest percentage of those who reached the LDL-C goal
of <100mg/dl were patients who used statins as opposed to
subjects who did not use statins medications (67% versus
58%, P = .05). They also had lower LDL-C levels at one-
year (93mg/dl for statins use versus 99mg/dl for non-statins
use, P = .04).Cholesterol 5
Table 1: Demographics of participants, Pharmacist Assisted Compliance Trial, Worcester Massachusetts, 2000–2005 (n = 689).
Condition Control Intervention P-value
Continuous Variable
Mean (SD) n Mean (SD) n
Age 60.29 (10.4) 338 60.38 (10.5) 351 .905
BMI from Catheterization Report 30.05 (5.7) 318 30.33 (5.8) 328 .536
BMI self report 1 year 30.11 (5.3) 239 29.81 (5.7) 253 .542
Change in BMI −0.03 (2.9) 226 −0.42 (3.0) 239 .149
Catheterization Report Severity Indexa 1.78 (0.9) 321 1.88 (0.9) 336 .189
Categorical Variable
% (Frequency) % (Frequency)
Gender: Female 40.24 (136) 338 40.17 (141) 351 1
Smoking status: Smoked within 1 year 27.76 (78) 281 20.40 (61) 299 .041
Education: High School or less 45.91 (118) 257 45.20 (127) 281 .931
Race: white 90.53 (306) 338 88.89 (312) 351 .532
Marital status: Married or living with partner 67.78 (162) 239 67.70 (174) 257 1
Employment: Fulltime or part-time 52.61 (151) 287 52.90 (164) 310 1
aCath Report Severity Index was calculated based on the number of diseased arteries [23, 24].
Table 2: Cholesterol measure at one-year, Pharmacist Assisted Compliance Trial, Worcester Massachusetts, 2000–2005 (n = 689).
Condition Control (n = 338) Intervention (n = 351)
% (Frequency) n % (Frequency) nP -value
LDL-C <100 goal 60.15 (157) 261 64.51 (189) 293 .293
LDL-C <70 goal 18.77 (49) 261 17.06 (50) 293 .657
Mean (SD) Mean (SD)
Total Cholesterol 172.85 (48.6) 274 167.27 (39.3) 297 .13
1 year LDL-C 97.79 (35.1) 261 94.47 (31.3) 293 .24
1 year HDL-C 42.61 (11.4) 272 42.30 (12.3) 297 .755
1 year Triglyceride 137.00 (8.96) 270 130.32 (8.87) 296 .29
Table 3: Statins, Beta-Blockers, and ACE Inhibitor medication compliance at one-year, Pharmacist Assisted Compliance Trial, Worcester
Massachusetts, 2000–2005 (n = 689).
Condition Control (n = 338) intervention (n = 351) P-value
Mean (SD) n Mean (SD) n
Statins
Number statin reﬁlls 6.13 (3.7) 179 6.35 (3.8) 196 .562
Statin CMA 0.90 (0.3) 162 0.88 (0.3) 173 .509
Number of prescriptions 2.41 (0.8) 223 2.55 (0.8) 238 .078
Total days on statin 290.53 (94.30) 179 291.20 (92.40) 196 .944
Beta Blockers
Number reﬁlls 5.80 (4.0) 189 6.34 (4.0) 207 .179
Beta-blocker CMA 0.91 (0.4) 157 0.97 (1.1) 180 .557
Total days on beta-blocker 283.19 (101.50) 189 287.55 (99.40) 207 .667
ACE Inhibitors
Number reﬁlls 5.73 (3.8) 146 6.23 (3.9) 179 .247
ACE CMA 0.93 (0.3) 126 1.02 (0.8) 157 .249
Total days on ACE 280.94 (93.40) 146 283.56 (95.00) 179 .803
% (Frequency) % (Frequency)
Monthlya statin prescription 69.83 (125) 179 70.41 (138) 196 .911
Monthlya beta-blocker prescription 59.79 (113) 189 64.25 (33) 207 .407
Monthlya ACE prescription 61.64 (90) 146 70.39 (126) 179 .1
∗a: An indicator of whether all prescriptions for the medication were monthly (or less) prescriptions (versus 90 day or something >30 days at any time).6 Cholesterol
Completion rates for pharmacist counseling calls were
high: 78% for 2 week calls; 80% for 1 month calls; 78% for 3
month calls; 72% for 6 month calls; 70% for 9 month calls.
Forty-eight percent completed all 5 calls and 62% completed
at least 4 calls. There was no apparent relationship between
interventiondose(i.e.,numberofinterventioncalls,thetotal
minutes of call time, and the average minutes of call time)
and the study outcomes (i.e., adherence or LDL-C level).
4. Discussion
Approximately two-thirds of subjects reached their LDL-
C goal one year after enrollment. There was no signiﬁcant
diﬀerence between the PI and UC conditions in LDL-C goal
attainment or statin medication adherence. However, the
adherence rate of the control condition was unexpectedly
high, and the level of adherence attained (CMA of 90%)
made further improvement by the intervention condition
diﬃcult to attain. Equally high adherence rates were seen
for beta-blocker and ACE inhibitor medications. These high
adherence rates may reﬂect a high level of patient concern
followingcatheterizationforCAD,orincreasingawarenessof
andattentiontomedicationadherenceonthepartofmedical
staﬀ.
Compared to other reports on adherence to medications
that show a small percentage of subjects reaching their LDL-
C goal, a greater percent of our study participants (over
60%) both reached their LDL-C goal and adhered to statin
prescriptions. However, failure to reach LDL-C target levels
remains common. Sueta and colleagues analyzed data from
a retrospective chart audit of 48,586 adult outpatients with
CHDfrom140medicalpractices(80%cardiologyonly)[25].
Of these patients, only 44% had annual diagnostic testing
of LDL-C, and of this 44%, only 25% (11% of the total)
achieved the target LDL-C level of <100mg/dl. Only 39% of
patients were taking lipid-lowering therapy, and appropriate
adherence was less common among the older than among
the younger patients.
Cohen and colleagues followed up on patients who had
beenhospitalizedforchestpainandfoundtohaveCHD[26].
At one-month, only 17% of those with high levels of total
cholesterol or LDL-C were being actively treated with either
diet or drugs. At one to two year follow-up that percentage
had reached 35%. The percentage who actually reached the
goal LDL-C level was unknown. In a study of 825 men and
women with CHD followed at 16 academic medical centers,
at the end of a three-year period of follow-up 55% of the
men but only 35% of the women were on pharmacologic
lipid-lowering therapy. The target LDL-C goal of less than
100mg/dl was achieved in only 31% of the men and only
12% of the women. The authors suggest that a gender bias
may exist in the use of such therapy [27]. According to the
recentNHANES,statinswerebeingusedbyonly19.6%ofUS
adults with high LDL-C levels in 1999-2000, it was increased
to27.3%in2001-2002, and35.9%in2003-2004, respectively
(P value for trend <.001). LDL-C goal was achieved by
49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-
2002, and 2003-2004, respectively (P trend<.001) [17]. Thus
the large majority of patients with known CHD or CHD risk
are inadequately treated for hyperlipidemia or, if treated, do
notadheretotheregimen.Reasonableestimatesbasedonthe
literature would suggest that no more than 30–40 percent are
treated and if treated, many do not adhere to lipid-lowering
medication, such that somewhere between only 15 and 30
percent achieve an LDL-C goal level of <100mg/dl [17, 25–
27].
Other trials have demonstrated the eﬀect of pharmacist
intervention on medication adherence. Erickson and col-
leagues found that over an average ﬁve-month follow-up,
signiﬁcant decreases in mean blood pressure were noted for
patients who were monitored by a clinical pharmacist and
a physician as compared to patients who received care from
a physician alone [28]. In this study, the pharmacist made
recommendations regarding pharmacotherapy to physicians
whose patients were in the intervention condition, while in
thecontrolcondition,physiciansreceivednosucheducation,
and interventions relating to pharmacotherapy were only
physician initiated. In a similar study conducted recently,
Borenstein and colleagues compared the eﬀectiveness of an
evidence-based systematic approach to hypertension care
involving comanagement of patients by primary care physi-
cians and clinical pharmacists versus usual care in reducing
blood pressure in patients with uncontrolled hypertension.
The study also resulted in improved blood pressure control
and reduced average visit costs/patient [29].
Inacrossoverstudydesign,Leeandcolleaguesalsofound
that a pharmacy care program led to increases in medication
adherence, medication persistence, and clinically meaningful
reductions in blood pressure, whereas discontinuation of
the program was associated with decreased medication
adherence and persistence [30].
Although adherence with statin medications was higher
thanexpected[22],physicianprescribedstatinsprescriptions
and dosages were often inadequate. Approximately 40%
of patients did not achieve an LDL-C level of <100mg/dl
in this study. In addition, only 53% and 56% of the
patients in the UC and PI conditions, respectively, were
prescribedstatinmedication.Therelativelylowpercentageof
patients prescribed statin medication may explain why many
participants did not reach their LDL-C goal.
This study has several strengths. It is a randomized
controlledclinicaltrialthatcollecteddetailedinformationon
medications and demographics. CMA was used to calculate
medication adherence. It accounts for discontinuation and
gaps between reﬁlls. Other methods of assessing adherence
are available, but tend to overestimate medication consump-
tion (pill counts) or are expensive and intrusive (electronic
monitors) [22].
There are several limitations of the study. First, although
the sample size of 689 in this study was suﬃcient to provide
ample power to detect outcomes, the sample size available
for LDL-C outcome was smaller (293 for the PI control and
260 for the control condition), and the power to detect what
level of LDL-C diﬀerence was decreased to 70%. This is
an important limitation. However, this study is one of the
largest clinical trials on this topic ever conducted. Second,
we used pharmacy reﬁll data that described the dispensing
of medication, but had no other available information toCholesterol 7
indicate whether dispensed medications were actually taken
by the patients. Likewise, we have no data on patients who
may have been prescribed medications that they never ﬁlled.
Third, we did not have data on cost of the medication and
insurancecoverage,whichalsoaﬀectsmedication adherence.
Fourth, our intervention focused on patients’ medication
adherence; although pharmacists made recommendations
about putting patients on statins to patients’ primary care
physicians via telephone, e-mail, and letters, this part of
intervention was not a primary focus of the study. Therefore,
no data are available as to whether physicians followed
the pharmacists’ recommendations. However, two previous
studies demonstrated the eﬀect of pharmacist intervention
on hypertensive medication adherence, in which pharma-
cists made recommendations to physicians regarding phar-
macotherapy for patients with uncontrolled hypertension.
Both trials concluded that hypertension care involving co-
management of patients by primary care physicians and
clinical pharmacists resulted in improved blood pressure
control and medication adherence [28, 29]. In light of the
lack of diﬀerences seen with the primary study endpoints
in the current study, future trials should consider evaluating
interventions that link pharmacists to physicians in an
attempt to inﬂuence physicians’ patterns for prescribing
lipid-lowering pharmacotherapy. Patients’ cardiologists were
not contacted in this study. This could be an area of
further research, i.e., would contact with the cardiologist
have led to a greater intervention eﬀect? Fifth, lipid levels
fall rapidly after an acute CHD event [31] and we did not
have LDL-C values at baseline. We do not know how many
patients met criteria for prescription for statin medication
based on the guideline at the time of their enrollment
in the study. Sixth, the majority of patients in this study
were Caucasian, thus limiting our ability to generalize to
other populations. Finally, one possibility for the high
adherence rate seen in the control condition may be due
to selection bias. Unfortunately, we do not have complete
demographic information to be able to compare participants
and nonparticipants. It is possible that there are selection
biases that we are not able to describe. By the very nature
o far a n d o m i z e dc o n t r o l l e dt r i a l ,r e q u i r i n gac o n s e n tp r o c e s s
and either formally or informally excluding individuals who
have memory impairment or who are unable for a variety
of reasons to provide consent postcatheterization, a selection
bias exist that favors the inclusion of individuals more likely
to be adherent to pharmacologic therapy.
5. Conclusions
A pharmacist-delivered intervention aimed only at
improving patient adherence to prescribed lipid-lowering
medications was unsuccessful in attaining target AHA-
recommended LDL-C goals. Achieving the goal of increasing
adherence to lipid-lowering pharmacotherapy was precluded
by very high adherence rates in the control condition.
However, statin prescription rates were lower than desirable.
Future pharmacist-delivered trials may be more eﬀective if
they are oriented towards inﬂuencing physicians’ prescribing
patterns, regarding prescription of appropriate medication.
Further studies of medication adherence also need to
concentrate on populations more likely to have diﬃculties
with medication-taking behavior.
Appendices
A. Patient-Centered Counseling Algorithm:
In-PatientVisit
Medication adherence should be assessed and emphasized
for statins (HMG-COA reductase inhibitors), β-blockers, and
ACE-inhibitors
Introduction. Hello, I am Dr. . I am the pharmacist
at the hospital.
Assess. Is this a good time to talk about your medicines?
I understand that you have been told that you have heart
disease.
(1) Knowledge
What do you know about the role of cholesterol in heart
disease?
What do you know about the role of diet and medication
in cholesterol control?
(2) Past experiences
Have you taken cholesterol-lowering medication in the
past?
What medications do you take at home?
What type of diﬃculties have you encountered with
regard to taking your medications in the past?
How did you deal with them?
Many people have diﬃculties with (go through
the “problems” checklist).
Have you experienced any of these?
(3) Motivations/Concerns
How do you feel about taking ?
It is helpful to identify your own reasons for doing
something.
Whataresomereasonsthatyoumighthavefortakingthe
medication?
What concerns you about taking ?
Advise
(1) Encouragement
I strongly advise that it is important for your health that
you take each day as (state medication
regimen.)
(2) Tailored advice
The beneﬁts of taking in your case can prevent
you from experiencing a heart attack.8 Cholesterol
Assist
(1) Correct misunderstandings
Some of the possible side eﬀects of this medication are
.
Based on our discussion so far, what questions do you
have?
(2) Provide support
Provide resources and materials (information packet on
diet, medication information, medication sheet and pillbox).
I know it is sometimes hard to take (additional) medications.
I’dliketohelpyouwiththis.I’moptimisticthatyou’llbeable
to take your medication and reduce your cholesterol level.
(3) Behavioral strategies
It is important that you take at these times
every day (state the goal for each medication).
(4) Stimulus control
What types of cues could you use to remind yourself to
take your medication?
Based on past experiences, are there any other situations
that could make it diﬃcult for you to take your medication
in the future? Keeping track of how often you take your
medication is very important. What might help you keep
track of whether or not you’ve taken your medication each
day?
(5) Address Problems/concerns
You mentioned that (state potential challenges
to medication intake identiﬁed by the patient) could poten-
tially interfere with your taking your medication. Can you
think of ways to deal with each of these problems? What
could you do to prevent this situation form aﬀecting your
ability to take your medication? (State one potential problem
at a time).
Consider a written behavioral contract.
Encourage use of support (medication sheet, pillbox,
other people).
What or who might help you?
H o ww i l lt h i sb eh e l p f u lt oy o u ?
So that I know that I have not forgotten to tell you
everything about your medicines, please tell me how you are
going to take ?
As we discussed, some things that help you take the
medication as intended are (mention discussed
strategies to enhance compliance).
I just want to take a minute to review the behavioral
contract with you.
What medication-related questions do you have for me?
Arrange Follow-up
I would like to call you to see how you are doing.
What is the best time (day of week and time of day) to
call you?
Schedule telephone calls and provide the patient with the
listofdatesandtimesthepharmacistwillbecalling(2weeks,
4 weeks, 12 weeks, 24 weeks, and 36 weeks). Ask the patient
to have all their medications and behavioral contract before
them prior to the pharmacist call.
B. Patient-CenteredCounselingAlgorithmFirst
Telephone Call (2 weeks)
Medication adherence should be assessed and emphasized
for statins (HMG-COA reductase inhibitors), β-blockers, and
ACE-inhibitors.
Introduction. H e l l o ,t h i si sD r . calling from the
UMass Memorial Medical Center. Can I please talk to
Mr./Ms. (state name of patient)? Mr./Ms. ,
we met about two weeks ago while you were in the hospital.
Assess
(1) General issues
How have you been doing?
Is this a good time to talk about your medications?
Do you have any questions about the role of cholesterol
in heart disease?
Do you have all your medications and the behavioral
contract in front of you?
(2) Recent Experiences with Medications
How are you doing with your medications?
How do you take ?
What questions do you have about your medications?
The last time we talked, you mentioned that
(name the problem the patient identiﬁed in the in-patient
visit) had the potential to interfere with your taking your
medications. Was a problem for you in the past 2
weeks? How did you deal with this (ask this question for each
problem reported by the patient)? Have you experienced any
other diﬃculty with regard to taking your medications?
(3) Motivations/Concerns
How do you feel about taking ? (Do this for
statins, beta-blockers and ACE inhibitors).
It is helpful to identify your own reasons for doing
something.
What are some reasons that you might have for taking
the medication? Do you have any concerns about taking
? (Do this for statins, beta-blcokers, and ACE
inhibitors).Cholesterol 9
Advise
(1) Encouragement
I strongly advise that it is important for your health that
you take each day as prescribed by your health care
provider.
(2) Tailored advise
The beneﬁts of taking in your case can prevent
you from experiencing a heart attack.
Assist
(1) Provide support
I know it is sometimes hard to take (additional) medica-
tions. I’d like to help you with this. I’m optimistic that you’ll
be able to take your medication and reduce your cholesterol
level.
(2) Address problems/concerns
You mentioned that (state any new challenges
to medication intake identiﬁed by the patient during this
call) interferes with your taking your medication. Can you
think of ways to deal with (state barrier)?
(3) Behavioral strategies
Review behavioral contact (what medications, when and
how taken, potential challenges, and ways to deal with them,
cues to remind patient of medications, tracking medications
intake).
Is there anything else that can be helpful to you?
What medication-related questions do you have for me?
Arrange Follow-up
According to my schedule, I will call you
(specify date and time of day) to see how you are doing. Is
this a good time?
Schedule next telephone call.
Remind patient to have their medications and behavioral
contract in front of them before the next telephone call.
C. Patient-Centered Counseling Algorithm:
Follow-upTelephoneCalls
Medication adherence should be assessed and emphasized
for statins (HMG-COA reductase inhibitors), β-blockers and
ACE-inhibitors. Reﬁll records and fasting lipid proﬁles should
be obtained prior to the 12-week, 24-week, and 36-week
calls. If necessary, please mail a revised medication sheet
and behavioral contract to the patient after each follow-up
telephone call.
Introduction. H e l l o ,t h i si sD r . calling from the
UMass Memorial Medical Center. Can I please talk to
Mr./Ms. (state name of patient)?
Assess
How have you been doing?
Is this a good time to talk about your medications?
Do you have all your medications and the behavioral
contract in front of you?
The last time we talked, you were taking .A r e
you still on this medication? What do you take it for?
How do you take it? What problems have you had with
taking this medication? Do you have any concerns about
taking this medication? How do you handle (state
problem/concern). Based on reﬁll records, if the patient has
switched from one agent to another, or if the dose has been
c h a n g e dt h e na c k n o w l e d g et h ec h a n g ea n da s kt h eq u e s t i o n s
above.
Advise
Given your high cholesterol (and other risk factors), I
strongly advise you to continue taking your medications
as (state drug regiment). The beneﬁts of taking
in your case can prevent you from experiencing a
heart attack.
Assist
The last time we talked you said that (state
challenges/potential barriers) was a problem? How did you
deal with this? What could you do in the future if/when you
lapse in medication taking? Keeping track of or monitoring
how often you take your medications is important. How are
you keeping track of the medications that you take? Refer
to behavioral contract. Encourage patient to use pillbox and
medication sheet.
So that I have not forgotten to tell you everything, please
tell me how you are going to take ?
As we discussed, some things that help you take the
medication as intended are (mention strategies to
enhance compliance).
What medication-related questions do you have for me?
Arrange Follow-up
According to my schedule, I will call you
(specifydateandtimeofday)toseehowyouaredoing.Isthis
a good time? Schedule next telephone call. Remind patient to
have their medications and behavioral contract in front of
them before the next telephone call.
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